MELBOURNE, Australia,
Nov. 15, 2011 /PRNewswire/ --
Australian based brokerage firm Lodge Group has released a positive
research note on NASDAQ and ASX listed Genetic Technologies Limited
(NASDAQ: GENE, ASX: GTG) following an update with management on the
roll-out of its lead molecular diagnostic cancer test in the
US.
According to Lodge, the Company's lead product BREVAGen™, a
predictive risk assessment tool for assessing women's risk of
developing breast cancer, is demonstrating early success within its
sales cycle in the US.
Importantly, the key drivers underpinning the future success of
BREVAGen as a standard tool in assessing women's risk of developing
breast cancer are being met.
Lodge believes Genetic Technologies has US management in place
capable of delivering on the Company's molecular diagnostics
strategy in North America, as well
as scaling the normal learning curve associated with any new
product launch.
Lodge noted key success factors in the BREVAGen roll-out
include: implementation in six of the eight initial launch
territories with plans for expansion, overall product receptiveness
by target audience (obstetricians and gynecologists), and
utilization of BREVAGen test results to gain insurance
reimbursement for MRI breast exams.
Lodge Partners predicts increased market opportunity and
acceptance for BREVAGen in their US Management Research Update
report (available upon request) and has a 12 Month Price Target of
AUD0.57 with an implied return of 320%.
About Genetic Technologies, Limited
Genetic Technologies was an early pioneer in recognizing
important new applications for "non-coding" DNA (Deoxyribonucleic
Acid). The Company has since been granted patents in 24
countries around the world, securing intellectual property rights
for particular uses of non-coding DNA in genetic analysis and gene
mapping across all genes in all species. Its business
strategy is the global commercialization of its patents through an
active out-licensing program and the global expansion of its
oncology and cancer management diagnostics portfolio. Genetic
Technologies is an ASX and NASDAQ listed company with operations in
the USA and Australia. For more information, please visit
http://www.gtglabs.com.
About Phenogen Sciences, Inc.
Phenogen Sciences, Inc., the U.S. division of Australia-based Genetic Technologies Limited,
is a pioneer in personalized healthcare. Phenogen provides
physicians and patients with personalized medical information, risk
assessments and insights for patient-specific health management in
the areas of oncology and women's health. Phenogen's lead
product, BREVAGen™ is the first predictive test that combines
clinical information and genetic factors to categorize a woman's
personal risk for developing breast cancer. For more
information, visit http://www.phenogensciences.com.
About Lodge Group
Headquartered in Melbourne,
Australia, Lodge Group is a specialist institutional
equities brokerage firm providing research, dealing and corporate
finance services to wholesale investors (institutional and
sophisticated) and corporate clients in Australia and internationally.
Established in 1994, Lodge is recognized as one of
Australia's pre-eminent equities
firms specializing in small to mid capitalization companies in the
healthcare sector. For more information, visit:
http://www.lodgepartners.com.au.
SOURCE Lodge Group
